Market openADR
Telix pharmaceutical/$TLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Telix pharmaceutical
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Ticker
$TLX
Sector
Trading on
Industry
Biotechnology
Headquarters
North Melbourne, Australia
Employees
423
Website
TLX Metrics
BasicAdvanced
$5.8B
189.46
$0.09
2.43
-
Price and volume
Market cap
$5.8B
Beta
2.43
52-week high
$30.36
52-week low
$13.61
Average daily volume
29K
Financial strength
Current ratio
2.776
Quick ratio
2.598
Long term debt to equity
98.548
Total debt to equity
102.329
Interest coverage (TTM)
11.30%
Management effectiveness
Return on assets (TTM)
5.33%
Return on equity (TTM)
13.92%
Valuation
Price to earnings (TTM)
189.459
Price to revenue (TTM)
11.586
Price to book
15.72
Price to tangible book (TTM)
58.72
Price to free cash flow (TTM)
-1,661.356
Growth
Revenue change (TTM)
55.85%
Earnings per share change (TTM)
798.14%
3-year revenue growth (CAGR)
368.92%
3-year earnings per share growth (CAGR)
-20.27%
TLX News
AllArticlesVideos
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
GlobeNewsWire·16 hours ago
Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud
Accesswire·20 hours ago
Telix Reports US$186M Q1 Revenue, Up 62% YOY
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Telix pharmaceutical stock?
Telix pharmaceutical (TLX) has a market cap of $5.8B as of April 29, 2025.
What is the P/E ratio for Telix pharmaceutical stock?
The price to earnings (P/E) ratio for Telix pharmaceutical (TLX) stock is 189.46 as of April 29, 2025.
Does Telix pharmaceutical stock pay dividends?
No, Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders as of April 29, 2025.
When is the next Telix pharmaceutical dividend payment date?
Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Telix pharmaceutical?
Telix pharmaceutical (TLX) has a beta rating of 2.43. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.